Table of Content

1. Introduction



2. Research & Methodology



3. Executive Summary



4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Inflammatory Bowel Disease Treatment Market


6. Market Share Analysis
6.1 Drug Class
6.2 Disease Indication
6.3 Distribution Channel
6.4 Country


7. Drug Class
7.1 TNF Inhibitors
7.2 Anti-Integrin
7.3 IL inhibitors
7.4 JAK inhibitors
7.5 Corticosteroids
7.6 Aminosalicylates
7.7 Others


8. Disease Indication
8.1 Ulcerative Colitis
8.2 Crohn’s Disease


9. Distribution Channel
9.1 Hospital Pharmacy
9.2 Retail Pharmacy
9.3 Online Pharmacy


10. Country
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium

10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 UAE


11. Porter’s Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Company Analysis
13.1 Abbott Laboratories
13.1.1 Overview
13.1.2 Key Persons
13.1.3 Recent Development & Strategies
13.1.4 Product Portfolio
13.1.5 Financial Insights

13.2 AbbVie Inc.
13.2.1 Overview
13.2.2 Key Persons
13.2.3 Recent Development & Strategies
13.2.4 Product Portfolio
13.2.5 Financial Insights

13.3 Allergan Therapeutics LLC
13.3.1 Overview
13.3.2 Key Persons
13.3.3 Recent Development & Strategies
13.3.4 Product Portfolio
13.3.5 Financial Insights

13.4 Bausch Health Companies Inc. (Salix Pharmaceuticals)
13.4.1 Overview
13.4.2 Key Persons
13.4.3 Recent Development & Strategies
13.4.4 Product Portfolio
13.4.5 Financial Insights

13.5 Bristol-Myers Squibb Company
13.5.1 Overview
13.5.2 Key Persons
13.5.3 Recent Development & Strategies
13.5.4 Product Portfolio
13.5.5 Financial Insights

13.6 Johnson & Johnson
13.6.1 Overview
13.6.2 Key Persons
13.6.3 Recent Development & Strategies
13.6.4 Product Portfolio
13.6.5 Financial Insights

13.7 Novartis AG
13.7.1 Overview
13.7.2 Key Persons
13.7.3 Recent Development & Strategies
13.7.4 Product Portfolio
13.7.5 Financial Insights

13.8 Pfizer Inc.
13.8.1 Overview
13.8.2 Key Persons
13.8.3 Recent Development & Strategies
13.8.4 Product Portfolio
13.8.5 Financial Insights



List of Figures

0

List of Tables

0